Literature DB >> 30232804

Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease.

Peter Ferenci1, Wolfgang Stremmel2, Anna Członkowska3, Ferenc Szalay4, André Viveiros5, Albert Friedrich Stättermayer1, Radan Bruha6, Roderick Houwen7, Tudor Lucian Pop8, Rudolf Stauber9, Michael Gschwantler10, Jan Pfeiffenberger2, Cihan Yurdaydin11, Elmar Aigner12, Petra Steindl-Munda1, Hans-Peter Dienes13, Heinz Zoller5, Karl Heinz Weiss2.   

Abstract

Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being liver disease and neuropsychiatric disturbances. This study investigated the clinical presentation in relation to mutations in a large cohort of patients with WD. A total of 1,357 patients (702 children, 655 adults; 1,172 index patients, 185 siblings, all with a Leipzig score ≥4, male/female: 679/678) were studied. The age and the symptoms at presentation were used as key phenotypic markers. Index patients were clinically classified as having either hepatic (n = 711) or neurologic disease (n = 461). Seven hundred fifteen (52.7%) patients had a liver biopsy at diagnosis. DNA was sequenced by the Genetic Analyzers ABI Prism 310 (Perkin Elmer) or 3500 (Applied Biosystems). Three hundred ninety-four different mutation combinations were detected. The most frequent mutation was H1069Q (c.3207C>A; allele frequency: 46.9%), followed by P767P-fs (c.2304dupC; 2.85%), P1134P-fs (c.3402delC; 2.8%), and R969Q (c.2755C>T; 2.18%). There was no correlation between mutations and individual clinical manifestation. There was a gender effect in index patients: Hepatic presentation was more common in females (male/female: 328/383) and neurologic presentation in males (259/202; P < 0.001). At diagnosis, 39.5% of children/adolescents (≤18 years) and 58% of adults already had cirrhosis. The presence of cirrhosis did not correlate with the genotype.
Conclusion: These findings refine and extend our understanding of the natural history and individual spectrum/manifestations of WD. Initially, there is asymptomatic hepatic involvement, which may progress and become symptomatic. Neurologic symptoms present many years later.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30232804     DOI: 10.1002/hep.30280

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

Review 1.  Clinical presentations of Wilson disease.

Authors:  Samuel Shribman; Thomas T Warner; James S Dooley
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Determination of copper poisoning in Wilson's disease using laser ablation inductively coupled plasma mass spectrometry.

Authors:  Sabine Weiskirchen; Philipp Kim; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  The Present and Future Challenges of Wilson's Disease Diagnosis and Treatment.

Authors:  Marcia Leung; Paul B Aronowitz; Valentina Medici
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

4.  ATP7B variant c.1934T > G p.Met645Arg causes Wilson disease by promoting exon 6 skipping.

Authors:  Daniele Merico; Carl Spickett; Matthew O'Hara; Boyko Kakaradov; Amit G Deshwar; Phil Fradkin; Shreshth Gandhi; Jiexin Gao; Solomon Grant; Ken Kron; Frank W Schmitges; Zvi Shalev; Mark Sun; Marta Verby; Matthew Cahill; James J Dowling; Johan Fransson; Erno Wienholds; Brendan J Frey
Journal:  NPJ Genom Med       Date:  2020-04-08       Impact factor: 8.617

5.  Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature.

Authors:  Gaurav V Sarode; Kyoungmi Kim; Dorothy A Kieffer; Noreene M Shibata; Tomas Litwin; Anna Czlonkowska; Valentina Medici
Journal:  Metabolomics       Date:  2019-03-12       Impact factor: 4.290

6.  Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.

Authors:  Luis García-Villarreal; Andrea Hernández-Ortega; Ana Sánchez-Monteagudo; Luis Peña-Quintana; Teresa Ramírez-Lorenzo; Marta Riaño; Raquel Moreno-Pérez; Alberto Monescillo; Daniel González-Santana; Ildefonso Quiñones; Almudena Sánchez-Villegas; Vicente Olmo-Quintana; Paloma Garay-Sánchez; Carmen Espinós; Jesús M González; Antonio Tugores
Journal:  J Gastroenterol       Date:  2020-11-07       Impact factor: 7.527

7.  mtDNA depletion-like syndrome in Wilson disease.

Authors:  Valentina Medici; Gaurav V Sarode; Eleonora Napoli; Gyu-Young Song; Noreene M Shibata; Andre O Guimarães; Charles E Mordaunt; Dorothy A Kieffer; Tagreed A Mazi; Anna Czlonkowska; Tomasz Litwin; Janine M LaSalle; Cecilia Giulivi
Journal:  Liver Int       Date:  2020-09-30       Impact factor: 5.828

8.  Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease.

Authors:  Christopher J Collins; Fan Yi; Remwilyn Dayuha; Phi Duong; Simon Horslen; Michelle Camarata; Ayse K Coskun; Roderick H J Houwen; Tudor L Pop; Heinz Zoller; Han-Wook Yoo; Sung Won Jung; Karl H Weiss; Michael L Schilsky; Peter Ferenci; Si Houn Hahn
Journal:  Gastroenterology       Date:  2021-02-25       Impact factor: 22.682

Review 9.  Therapeutic strategies in Wilson disease: pathophysiology and mode of action.

Authors:  Wolfgang Stremmel; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2021-04

10.  The impact of Wilson disease on myocardial tissue and function: a cardiovascular magnetic resonance study.

Authors:  Janek Salatzki; Isabelle Mohr; Jannick Heins; Mert H Cerci; Andreas Ochs; Oliver Paul; Johannes Riffel; Florian André; Kristóf Hirschberg; Matthias Müller-Hennessen; Evangelos Giannitsis; Matthias G Friedrich; Uta Merle; Karl Heinz Weiss; Hugo A Katus; Marco Ochs
Journal:  J Cardiovasc Magn Reson       Date:  2021-06-24       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.